Category: Uncategorized

September 05, 2024 RESEARCH TRIANGLE PARK, N.C., Sept. 05, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will be participating in upcoming investor conferences. The management team will also host one-on-one investor meetings at the conferences. Conference Details: Event: H.C. Wainwright Global Investment ConferenceDate: September 11, 2024Time: Company Presentation […]

Read More… from FENNEC PHAMACEUTICALS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

~ Achieved Second Quarter 2024 Total Net Revenues of $7.3 Million ~ ~ Appointed Jeffrey S. Hackman as Chief Executive Officer (CEO) and Member of the Board of Directors ~ ~ Company Has Approximately $43 Million in Cash, Cash Equivalents, and Investment Securities ~ ~ Management to Host Conference Call Today at 8:30 a.m. ET ~ Research […]

Read More… from FENNEC PHARMACEUTICALS REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

~ Company to Also Participate in 2024 Wedbush PacGrow Healthcare Conference ~ RESEARCH TRIANGLE PARK, N.C., August 6, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its second quarter 2024 financial results and provide a business update before the opening of the […]

Read More… from FENNEC PHARMACEUTICALS TO REPORT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 13, 2024

~ Accomplished Industry Leader Brings Extensive Commercialization and Oncology Expertise ~ ~ Assumes Leadership Role at Critical Time to Expand Use of PEDMARK®, the First and Only Approved Treatment to Reduce the Risk of Cisplatin-Induced Ototoxicity ~ RESEARCH TRIANGLE PARK, N.C., August 5, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty […]

Read More… from FENNEC PHARMACEUTICALS APPOINTS JEFFREY S. HACKMAN AS CHIEF EXECUTIVE OFFICER AND DIRECTOR  

RESEARCH TRIANGLE PARK, N.C., July 1, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that Adrian Haigh has departed from his position as Fennec’s Chief Operating Officer as of June 30, 2024. After nine years as an independent director, in August 2023, Adrian joined the Fennec leadership […]

Read More… from FENNEC PHARMACEUTICALS ANNOUNCES MANAGEMENT CHANGE

Research Triangle Park, NC — (Marketwired) –June 25, 2024 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated April 29, 2024 (the “Circular”) for the Annual General Meeting of Shareholders were elected as directors of the Company at the Annual General Meeting of Shareholders […]

Read More… from FENNEC ANNOUNCES RESULTS OF ANNUAL MEETING

~ Achieved First Quarter 2024 Total Net Revenues of $25.4 Million, Including $18.0 Million in Licensing Revenue from Recently Announced Norgine Transaction ~ ~ Executed Exclusive Licensing Agreement with Norgine to Commercialize PEDMARQSI™ in Europe, Australia, and New Zealand ~ ~ Amended PEDMARKÒ Permanent J-code 0208 Became Effective April 1, 2024 ~ ~ Company Has Approximately $51 Million […]

Read More… from FENNEC PHARMACEUTICALS REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

RESEARCH TRIANGLE PARK, N.C., May 7, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its first quarter 2024 financial results before the opening of the U.S. financial markets on Tuesday, May 14, 2024. Management will host a conference call and webcast that […]

Read More… from FENNEC PHARMACEUTICALS TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON MAY 14, 2024

~ Achieved PEDMARK® Full-Year 2023 Net Product Sales of $21.3 Million, Including $9.7 Million in Net Product Sales in the Fourth Quarter of 2023 ~ ~ Entered Into Exclusive Licensing Agreement to Commercialize PEDMARQSI® in Europe, Australia and New Zealand for Approximately $43 Million Upfront and Up to Approximately $230 Million in Additional Commercial and […]

Read More… from FENNEC PHARMACEUTICALS REPORTS FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

March 19, 2024 RESEARCH TRIANGLE PARK, N.C., March 19, 2024 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced that the Company will release its full year and fourth quarter 2023 financial results before the opening of the U.S. financial markets on Thursday, March 21, 2024. Management will host a conference call and […]

Read More… from FENNEC PHARMACEUTICALS TO REPORT FULL YEAR AND FOURTH QUARTER 2023 FINANCIAL RESULTS ON MARCH 21, 2024